((自动化翻译由路透提供,请见免责声明 ))
10月3日 - ** Aldeyra Therapeutics 股价盘前上涨 1.9% 至 5.40 美元
** 该公司称已向美国食品及药物管理局重新提交了干眼症药物的审批申请
** 去年,美国食品和药物管理局拒绝批准 (link) 药物 reproxalap
** 截至上次收盘,股价累计上涨 51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.